Civitas commences CVT-301 Phase 2a trial in Parkinsons disease Civitas Therapeutics ?propecia 1mg.

Civitas commences CVT-301 Phase 2a trial in Parkinson’s disease Civitas Therapeutics, Inc ?propecia 1mg ., a privately-held pharmaceutical company developing transformative therapeutics using the ARCUS respiratory delivery platform, today the initiation of a Stage announced 2a medical trial in Parkinson’s disease patients evaluating CVT-301, an inhaled formulation of levodopa , for the rapid relief from motor fluctuations. CVT-301 provides immediate starting point of a large and precise dosage of L-dopa.